JP2023552195A5 - - Google Patents
Info
- Publication number
- JP2023552195A5 JP2023552195A5 JP2023533878A JP2023533878A JP2023552195A5 JP 2023552195 A5 JP2023552195 A5 JP 2023552195A5 JP 2023533878 A JP2023533878 A JP 2023533878A JP 2023533878 A JP2023533878 A JP 2023533878A JP 2023552195 A5 JP2023552195 A5 JP 2023552195A5
- Authority
- JP
- Japan
- Prior art keywords
- peg
- lnp
- lipid
- immune cell
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121801P | 2020-12-04 | 2020-12-04 | |
| US63/121,801 | 2020-12-04 | ||
| US202163166205P | 2021-03-25 | 2021-03-25 | |
| US63/166,205 | 2021-03-25 | ||
| US202163169395P | 2021-04-01 | 2021-04-01 | |
| US202163169296P | 2021-04-01 | 2021-04-01 | |
| US63/169,395 | 2021-04-01 | ||
| US63/169,296 | 2021-04-01 | ||
| US202163172024P | 2021-04-07 | 2021-04-07 | |
| US63/172,024 | 2021-04-07 | ||
| PCT/US2021/072745 WO2022120388A2 (en) | 2020-12-04 | 2021-12-03 | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026078720A Division JP2026129957A (ja) | 2020-12-04 | 2026-05-08 | イオン化可能なカチオン性脂質および脂質ナノ粒子ならびにその合成および使用の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023552195A JP2023552195A (ja) | 2023-12-14 |
| JP2023552195A5 true JP2023552195A5 (cg-RX-API-DMAC10.html) | 2024-12-10 |
Family
ID=79287892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533878A Pending JP2023552195A (ja) | 2020-12-04 | 2021-12-03 | イオン化可能なカチオン性脂質および脂質ナノ粒子ならびにその合成および使用の方法 |
Country Status (12)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12011507B2 (en) | 2022-04-01 | 2024-06-18 | Nanovation Therapeutics Inc. | MRNA delivery composition |
| CN119630705A (zh) * | 2022-06-14 | 2025-03-14 | 阿布林克斯有限公司 | 靶向t细胞受体的免疫球蛋白单可变结构域 |
| WO2024079046A1 (en) * | 2022-10-10 | 2024-04-18 | Zelarion Malta Limited | Anti-cd2 antibodies for type 1 diabetes |
| EP4630061A1 (en) * | 2022-12-08 | 2025-10-15 | Nanovation Therapeutics Inc. | Lipid nanoparticles comprising elevated neutral lipid and a targeting moiety for targeted delivery of nucleic acid |
| JP2026512425A (ja) * | 2023-03-30 | 2026-04-16 | オーエスイー・イミュノセラピューティクス | 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用 |
| WO2024200820A1 (en) * | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| EP4694867A2 (en) * | 2023-04-13 | 2026-02-18 | Massachusetts Institute of Technology | Lipid nanoparticles for delivery of agents |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| EP4758176A1 (en) * | 2023-07-31 | 2026-06-17 | Jibe Therapeutics, Inc. | Compositions for redirecting immunoglobulins to immune cells |
| AU2024342487A1 (en) * | 2023-09-13 | 2026-04-30 | Tessera Therapeutics, Inc. | Lipid nanoparticles for delivery of therapeutic payloads to cells |
| KR20260094765A (ko) * | 2023-10-13 | 2026-06-23 | 나노셀 테라퓨틱스 홀딩스 비.브이. | 면역 이펙터 세포로의 제제 전달을 위한 수단 및 방법 |
| IL330028A (en) * | 2023-12-13 | 2026-08-01 | Tidal Therapeutics Inc | Ionizable cationic lipids and lipid nanoparticles, and methods for their synthesis and use |
| IL328626A (en) * | 2023-12-15 | 2026-07-01 | Capstan Therapeutics Inc | Humanized anti-CD8 antibodies and their uses |
| AU2024413489A1 (en) * | 2023-12-29 | 2026-07-16 | Samyang Biopharm Corporation | Nanoparticle composition for drug delivery |
| WO2025169168A1 (en) * | 2024-02-09 | 2025-08-14 | Nanocell Therapeutics Holdings B.V. | Extracorporeal transfection of immune effector cells |
| WO2025184694A1 (en) * | 2024-03-04 | 2025-09-12 | The University Of Melbourne | Nanoparticles and uses thereof |
| US20250381150A1 (en) | 2024-03-08 | 2025-12-18 | Genzyme Corporation | Lipid nanoparticles |
| WO2025213153A2 (en) * | 2024-04-05 | 2025-10-09 | Transcera Inc. | Compounds for lysosomal degradation of target proteins |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026029040A1 (ja) * | 2024-07-29 | 2026-02-05 | 日油株式会社 | アミノ脂質及び脂質ナノ粒子 |
| WO2026030375A2 (en) | 2024-07-30 | 2026-02-05 | Genzyme Corporation | Lipid nanoparticles and methods of manufacture and use thereof |
| WO2026080826A1 (en) * | 2024-10-10 | 2026-04-16 | Generation Bio Co. | Bispecific stealth lipid nanoparticle compositions for cell targeting |
| WO2026083328A1 (en) | 2024-10-18 | 2026-04-23 | Precision Biosciences, Inc. | Base editing nucleotide sequences using homology directed repair |
| WO2026083329A1 (en) | 2024-10-18 | 2026-04-23 | Precision Biosciences, Inc. | Methods of nuclease-initiated homology directed repair and replacement and compositions and uses thereof |
| WO2026090137A1 (en) * | 2024-10-22 | 2026-04-30 | Genzyme Corporation | Process for inserting targeting ligand into a lipid nanoparticle encapsulating nucleic acid and compositions produced therefrom |
| WO2026099382A1 (en) * | 2024-11-06 | 2026-05-15 | Nanocell Therapeutics Holdings B.V. | Means and methods for delivery of agents to immune effector cells |
| WO2026142951A1 (en) | 2024-12-23 | 2026-07-02 | Genzyme Corporation | Pharmaceutical system |
| WO2026141629A1 (ja) * | 2024-12-27 | 2026-07-02 | 日東電工株式会社 | 脂質ナノ粒子 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| EP0568332B1 (en) | 1992-04-28 | 1999-07-28 | Sumitomo Rubber Industries, Ltd. | Solid golf ball |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| EP0970128A1 (en) | 1997-03-21 | 2000-01-12 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
| US6849258B1 (en) | 1997-07-18 | 2005-02-01 | Universite Catholique De Louvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
| NZ545314A (en) | 2003-08-04 | 2009-03-31 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble CTLA4 molecule |
| JP2007521234A (ja) | 2003-08-12 | 2007-08-02 | ウィリアム エム ヤーブロー | 尋常性ざ瘡の治療薬及び使用方法 |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン.ヴェー. | Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
| WO2009100140A1 (en) | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| AU2009290543B2 (en) | 2008-09-12 | 2015-09-03 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| MX2011010681A (es) | 2009-04-10 | 2012-01-20 | Ablynx Nv | Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r. |
| ES2613498T3 (es) * | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
| US8569256B2 (en) * | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| US20130017223A1 (en) | 2009-12-18 | 2013-01-17 | The University Of British Columbia | Methods and compositions for delivery of nucleic acids |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| CA3141978A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| WO2015011633A1 (en) * | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| HUE050159T2 (hu) | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| LT3248986T (lt) | 2014-05-16 | 2022-03-25 | Ablynx Nv | Imunoglobulino kintami domenai |
| EP3247398A4 (en) | 2015-01-23 | 2018-09-26 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| WO2016176330A1 (en) * | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| EP3303598B1 (en) * | 2015-05-26 | 2025-03-19 | Ramot at Tel-Aviv University Ltd. | Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes |
| HUE067372T2 (hu) | 2015-06-29 | 2024-10-28 | Acuitas Therapeutics Inc | Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására |
| US20180271998A1 (en) * | 2015-12-04 | 2018-09-27 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
| CN111542338B (zh) * | 2017-12-27 | 2024-06-18 | 武田药品工业株式会社 | 含核酸脂质纳米粒子及其用途 |
| US20200149070A1 (en) * | 2018-04-24 | 2020-05-14 | Ligandal, Inc. | Methods and compositions for genome editing |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAx抗-CD3抗體及其用途 |
| JP2021530545A (ja) | 2018-07-23 | 2021-11-11 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | 同種異系の細胞療法における抗−cd2抗体薬物コンジュゲート(adc)の使用 |
-
2021
- 2021-12-02 PH PH1/2023/500013A patent/PH12023500013A1/en unknown
- 2021-12-03 KR KR1020237022607A patent/KR20230123480A/ko active Pending
- 2021-12-03 MX MX2023006604A patent/MX2023006604A/es unknown
- 2021-12-03 IL IL303373A patent/IL303373A/en unknown
- 2021-12-03 CA CA3201219A patent/CA3201219A1/en active Pending
- 2021-12-03 US US17/542,348 patent/US20220218614A1/en active Pending
- 2021-12-03 EP EP21840391.3A patent/EP4256067A2/en active Pending
- 2021-12-03 JP JP2023533878A patent/JP2023552195A/ja active Pending
- 2021-12-03 WO PCT/US2021/072745 patent/WO2022120388A2/en not_active Ceased
- 2021-12-03 AU AU2021393593A patent/AU2021393593A1/en active Pending
- 2021-12-06 TW TW110145547A patent/TW202241458A/zh unknown
-
2023
- 2023-06-05 CO CONC2023/0007408A patent/CO2023007408A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7542257B2 (ja) | 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法 | |
| US20160361317A1 (en) | Compositions comprising rank/rankl antagonists and related compounds for treating pain | |
| JP2025505603A (ja) | 細胞への標的化送達のための薬剤および方法 | |
| US20250281405A1 (en) | Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof | |
| KR20250007062A (ko) | Epo 수용체 효능제 및 길항제 | |
| CN117642429A (zh) | 用于治疗cldn6阳性癌症的编码cldn6和cds结合元件的试剂 | |
| WO2022067091A1 (en) | Systems and methods for expressing biomolecules in a subject | |
| US20250235532A1 (en) | Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof | |
| WO2020053325A1 (en) | Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof | |
| WO2025087303A1 (en) | Lipid nanoparticle with non-covalent bifunctional binders for active targeting | |
| JP2012506371A (ja) | 樹状細胞を標的とするための組成物 | |
| JP2024522607A (ja) | 治療薬の標的化送達のための組成物及び方法 | |
| RU2024139944A (ru) | Ионизируемые катионные липиды и липидные наночастицы, а также способы их синтеза и применения | |
| JP2024522316A5 (cg-RX-API-DMAC10.html) | ||
| US20250381150A1 (en) | Lipid nanoparticles | |
| CN120359047A (zh) | 用于靶向递送治疗剂的组合物和方法 | |
| EP4652282A2 (en) | Compositions for targeting muscle cells and uses thereof | |
| WO2024092352A1 (en) | Compositions that recruit and activate antigen presenting cells | |
| HK40113807A (en) | Agents and methods for targeted delivery of nucleic acids to cells | |
| HK40114081A (en) | Agents and methods for targeted delivery to cells | |
| CN118973618A (zh) | 用于将核酸靶向递送至细胞的药剂和方法 | |
| CN118973619A (zh) | 用于靶向递送至细胞的药剂和方法 | |
| WO2026085300A1 (en) | Compositions and methods | |
| WO2026034573A1 (ja) | Cd320に結合する抗体およびその断片、並びに前記抗体を含む抗体薬物コンジュゲート | |
| WO2022097634A1 (ja) | 血管新生依存性疾患治療に使用される医薬用組成物 |